deltatrials
Completed NA INTERVENTIONAL 1-arm NCT02807857

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care (PREFER)

Sponsor: Novartis Pharmaceuticals

Conditions Chronic Heart Failure (CHF)
Interventions Standard care
Updated 17 times since 2017 Last updated: Feb 2, 2021 Started: Jul 7, 2016 Primary completion: Mar 23, 2018 Completion: Mar 23, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Chronic Heart Failure (CHF), this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Oct 2020 · 24 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed NA

  2. Sep 2024 — Sep 2025 [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. Dec 2021 — Jul 2024 [monthly]

    Completed NA

  5. Mar 2021 — Dec 2021 [monthly]

    Completed NA

▶ Show 12 earlier versions

  1. Feb 2021 — Mar 2021 [monthly]

    Completed NA

    Status: Unknown Status → Completed · Phase: PHASE4 → NA

  2. Jan 2021 — Feb 2021 [monthly]

    Unknown Status PHASE4

  3. Oct 2020 — Jan 2021 [monthly]

    Unknown Status PHASE4

    Status: Recruiting → Unknown Status

  4. Oct 2018 — Oct 2020 [monthly]

    Recruiting PHASE4

  5. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE4

  6. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE4

  7. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  8. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE4

  9. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE4

  10. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE4

  11. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE4

  12. Jan 2017 — May 2017 [monthly]

    Recruiting PHASE4

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , A Estrada, Spain , Aarschot, Belgium , Alcúdia, Spain , Alicante, Spain , Alveringem, Belgium , Alytus, Lithuania , Arras, France , Balatonkeresztúr, Hungary , Beersheba, Israel and 150 more locations